SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9186373
APP PUB NO 20140010781A1
SERIAL NO

13977453

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
APEIRON BIOLOGICS GMBHVIENNA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Haslinger, Isabella Vienna, AT 2 5
Lametschwandtner, Günther Vienna, AT 3 7
Loibner, Hans Vienna, AT 61 199
Schuster, Manfred Schrick, AT 47 939
Seidl, Sandra Vienna, AT 2 5

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 17, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00